Format

Send to

Choose Destination
BMC Cancer. 2015 Jun 10;15:466. doi: 10.1186/s12885-015-1481-9.

A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment.

Author information

1
Institute of Radiation Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstaedter Landstr. 1, 85764, Neuherberg, Germany. natasa.anastasov@helmholtz-muenchen.de.
2
Institute of Radiation Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstaedter Landstr. 1, 85764, Neuherberg, Germany. ines.hoefig@helmholtz-muenchen.de.
3
Institute of Radiation Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstaedter Landstr. 1, 85764, Neuherberg, Germany. vanja.radulovic@helmholtz-muenchen.de.
4
Insphero AG, Schlieren, Switzerland. simon.stroebel@insphero.com.
5
Sirion Biotech GmbH, Martinsried, Germany. Salomon@sirion-biotech.de.
6
Insphero AG, Schlieren, Switzerland. jan.lichtenberg@insphero.com.
7
Assay Development and Screening Platform, Institute of molecular Toxicology and Pharmacology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. ina.rothenaigner@helmholtz-muenchen.de.
8
Assay Development and Screening Platform, Institute of molecular Toxicology and Pharmacology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. kamyar.hadian@helmholtz-muenchen.de.
9
Insphero AG, Schlieren, Switzerland. jens.kelm@insphero.com.
10
Sirion Biotech GmbH, Martinsried, Germany. thirion@sirion-biotech.de.
11
Institute of Radiation Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstaedter Landstr. 1, 85764, Neuherberg, Germany. atkinson@helmholtz-muenchen.de.
12
Chair of Radiation Biology, Technical University of Munich, Munich, Germany. atkinson@helmholtz-muenchen.de.

Abstract

BACKGROUND:

Radiation resistance presents a challenge to the effective treatment of cancer. If therapeutic compounds were capable of resensitizing resistant tumours then a concurrent chemo-radiation treatment could be used to overcome radiation resistance.

METHODS:

We have developed a phenotypic assay to investigate the response of radiation resistant breast cancer cells grown in 3D-microtissue spheroids to combinations of radiation and established chemotherapeutic drugs. The effects were quantified by real time high content imaging of GFP detection area over 14 days. Ten established chemotherapeutic drugs were tested for their ability to enhance the effects of radiation.

RESULTS:

Of ten analysed chemotherapeutics, vinblastine was the most effective compound, with docetaxel and doxorubicine being less effective in combination with radiation. To investigate the response in a model closer to the in vivo situation we investigated the response of heterotypic 3D microtissues containing both fibroblasts and breast cancer cells. Drug treatment of these heterotypic 3D cultures confirmed treatment with radiation plus vinblastine to be additive in causing breast cancer growth inhibition. We have validated the screen by comparing radiation sensitizing effects of known chemotherapeutic agents. In both monotypic and heterotypic models the concurrent treatment of vinblastine and radiation proved more effective inhibitors of mammary cancer cell growth. The effective concentration range of both vinblastine and radiation are within the range used in treatment, suggesting the 3D model will offer a highly relevant screen for novel compounds.

CONCLUSIONS:

For the first time comfortable 3D cell-based phenotypic assay is available, that allows high throughput screening of compounds with radiation therapy modulating capacity, opening the field to drug discovery.

PMID:
26059545
PMCID:
PMC4460881
DOI:
10.1186/s12885-015-1481-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center